Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy.

1995278 citationsJournal Article

Authors

Pieter Sonneveld · Rotterdam University of Applied Sciences

Maria de Ridder

Abstract

CHOP is well tolerated in elderly patients with advanced intermediate- or high-grade NHL and its NDI is not seriously impaired. Treatment with CHOP (doxorubicin) results in better CR and survival rates than CNOP (mitoxantrone). CHOP should be recommended for elderly patients with high-risk NHL.

Topics & Keywords

Lymphoma Diagnosis and Treatment Lung Cancer Treatments and Mutations Lung Cancer Research Studies

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

Volume 13, Issue 10, pp. 2530-2539

DOI: 10.1200/jco.1995.13.10.2530

Field-Weighted Citation Impact: 6.41